GB2130585A - S isomer of betaxolol, its preparation and its application in therapy - Google Patents

S isomer of betaxolol, its preparation and its application in therapy Download PDF

Info

Publication number
GB2130585A
GB2130585A GB08331038A GB8331038A GB2130585A GB 2130585 A GB2130585 A GB 2130585A GB 08331038 A GB08331038 A GB 08331038A GB 8331038 A GB8331038 A GB 8331038A GB 2130585 A GB2130585 A GB 2130585A
Authority
GB
United Kingdom
Prior art keywords
betaxolol
pharmaceutically
acid addition
acceptable acid
preparation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
GB08331038A
Other versions
GB8331038D0 (en
GB2130585B (en
Inventor
Jean Binet
Philippe Manoury
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Synthelabo SA
Original Assignee
Synthelabo SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Synthelabo SA filed Critical Synthelabo SA
Publication of GB8331038D0 publication Critical patent/GB8331038D0/en
Publication of GB2130585A publication Critical patent/GB2130585A/en
Application granted granted Critical
Publication of GB2130585B publication Critical patent/GB2130585B/en
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

(S)(-) Betaxolol of the formula: <IMAGE> and its pharmaceutically-acceptable acid addition salts, are new compounds which are, in particular, useful for the treatment of cardiovascular diseases and glaucoma. (S)(-) Betaxolol can be prepared by reacting 4-(2-cyclopropylmethoxyethyl)phenol with the tosyl derivative of (S)-2-phenyl-5-hydroxymethyl-3- isopropyloxazolidine.

Description

SPECIFICATION S isomer of betaxolol, its preparation and its application in therapy The present invention relates to the S isomer of betaxolol, its preparation and its application in therapy, e.g.
pharmaceutical compositions containing it.
The compound of the invention is the (S)(-) isomer of betaxolol corresponding to the formula:
and its pharmaceutically-acceptable acid addition salts.
The compound of the invention is prepared, according to a feature of the invention, by the process which comprises reacting 4-(2-cyclopropylmethoxyethyl)-phenol with the (S)-oxazolidine of the formula:
in an organic solvent, such as dimethylformamide, in the presence of a base such as sodium hydroxide, potassium hydroxide or, preferably, sodium hydride.
4-(2-Cyclopropylmethoxyethyl)-phenol can be prepared in the manner described in our French Patent No.
75/33899.
Pharmaceutically-acceptable acid addition salts of the S isomer of betaxolol, e.g. methanesulphonates, mandelates, fumarates, oxalates, maleates, malonates, citrates, hydrochlorides, hydrobromides and hydrolodides, may be obtained by methods known per se, for example by treatment of the isomer base with the appropriate acid in a solvent medium, e.g. an alkanol or ether, or mixtures thereof.
By the term 'methods known per se' as used in this specification is meant methods heretofore used or described in the literature.
The Example which follows illustrates the process of the invention.
Example 22.19 (0.1 mol) of (S)-2-phenyl-5-hydroxymethyl-3-isopropyloxazolidine of the formula:
(described by Baldwin petal., J. Med. Chem. 1979, Viol.22, No. 11) are dissolved in 37.5 ml of pyridine, and 19.0g of tosyl chloride are added in portions, the temperature being kept at about 25"C.
When the addition has ended, the reaction mixture is stirred for 2 hours at ambient temperature and a solution of 13.89 of K2C03 in 75 ml of water is then added cautiously. The mixture is extracted 3 times with 100 ml of CH2C12, the organic phase is dried with MISS04 and filtered, and the filtrate is evaporated at a temperature below 50"C, initially under a water pump vacuum and then under 0.1 mm of mercury. This gives 33.99 of an oil, which is used in the crude state for the subsequent reaction.
A solution of 17.39 (0.09 mol) of 4-(2-cyclopropylmethoxyethyl)-phenol in 50 ml of dimethylformamide (DMF) is added dropwise to a suspension of 4.89 (0.1 mol) of 50% NaH in 50 ml of DMF, and the mixture is stirred until the evolution of hydrogen has ceased. The mixture is cooled using a bath of iced water, and a solution of 33.99 of the previously obtained oil in 50 ml of DMF is added in portions; the mixture is then heated at 60-70"C for 2 hours. The mixture is left to stand overnight and heated again at a temperature of about 60"C for 4 hours. The mixture is cooled, poured onto ice and extracted twice with diethyl ether. The ether phase is washed with water, dried over MgSO4 and filtered, and the filtrate is evaporated.The oil is taken up in water and the mixture is acidified with 50 ml of concentrated HCI, stirred for 1/2 hour at ambient temperature and then extracted twice with diethyl ether.
The aqueous phase is rendered alkaline with sodium hydroxide and extracted with diethyl ether. The ether phase is washed with water, dried over MgSO4 and filtered, and the filtrate is evaporated.
The residual oil is taken up in diethyl ether, a stoichiometric amount of maleic acid is added to this solution, and the maleate salt of the (S)(-) isomer of betaxolol crystallises slowly. The maleate melts at 96do, [2D0 -16.2' (C = 1.87%; CH30H) (S)(-)-Betaxolol is prepared from its maleate salt by alkalinisation with a dilute solution of sodium hydroxide. It is an oil; [a]2D5 = -0.5' (C = 3.56%, CH30H) The compound of the invention was subjected to pharmacological tests in the cardiovascular field and in the treatment of glaucoma.
(1) Effect of (S)K)-betaxo,ol maleate on the chronotropic and inotropic responses ofguinea-pig atrium to isoprenaline, after depletion of the catecholamines The method used is similar to that recommended by O'Donnell and Wanstall (1979).
Guinea-pigs (Hartley), weighing 250 to 300g, are given a subcutaneous injection of syrosingopine (5.0 mg/kg) approximately 18 hours before the start of the experiment, in order to cause depletion of catecholamines in the peripheral tissue reserves. The guinea-pigs are sacrificed by dislocation of the cervix and the whole hearts are removed and placed in a Krebs solution, at ambient temperature (21"C), oxygenated with a mixture containing 95% of O2 and 5% of CO2. The composition of the solution, in mM, is: NaCI 114.0; KCI 4.7; CaCI2 2.5; KH2PO4 1.2; MgSO4 1.2; NaHCO3 25.0; glucose 11.7. Ascorbic acid (1.1 mM) is added to the isoprenaline solutions in order to reduce the oxidation thereof. After the two atria have been separated, each is attached by its base to a hook fixed to a support.A wire is then attached to the apex of each atrium, and the atria are immersed in an isolated organ bath containing 30 ml of Krebs solution at 37"C.
They are connected to a displacement force transducer (Grass, model TFO3 C) by the wire attached to the apex, and are placed under a rest tension of 0.5g. The right atrium beats spontaneously whereas the left atrium is driven electrically by a current consisting of 2 millisecond pulses of about 30 V (supramaximum voltage) delivered 120 times/minute. The atrial rhythm and the contractile force are recorded on a polygraph (Grass 79B).
The atria are left to stand in the isolated organ bath for 30 minutes. The mechanisms of neuronal and extraneuronal capture of the catecholamines are then blocked by keeping the atria in contact with phenoxybenzamine (50 M) for 30 minutes. After washing with Krebs solution, each preparation is sensitised by adding isoprenaline (0.3 AM) 20 minutes before the first curve of concentration-effect of the isoprenaline is plotted. The isoprenaline is added to the bath in cumulative increasing concentrations (semi-log interval). The maximum changes in the contractile force and the heart rate which are caused by each dose are the values used for analysing the results.
Approximately 45 minutes after the first curve of concentration-response to the isoprenaline has been plotted, when the parameters studied have returned to their initial values, the preparations are immersed for 30 minutes in a Krebs solution containing (S)(-)-betaxolol maleate (0.3 WM).
Each change in the atrial rhythm or the contractile force which is generated by the isoprenaline is expressed as a percentage of the response of the atrium to a supramaximum dose of isoprenaline. A more detailed analysis of the results is only carried out if the second dose/effect curve is parallel to the control curve and if the maxima of the two curves do not differ more than + 20%.
The pA2 values are calculated according to van Rossum (1963). The average pA2 values are compared by variance analysis. The differences between the averages are considered to be significant when t corresponds to p < 0.05.
The pA2 value of the compound of the invention is - 8.76 t 0.06 in respect of the chronotropic effects on the isoprenaline (spontaneously beating atrium), and - 8.78 t 0.12 in respect of the inotropic effects telectrically stimulated atrium) of the isoprenaline.
(2) Effect of (SJ(-)-betaxolol maleate on glaucoma Drops are prepared by dissolving a sufficient amount of the maleate salt of the compound of the invention in distilled water so as to give solutions containing 0.1%, 0.5%, 0.75% and 2% of compound. 2 drops of solution are administered to a normal rabbit eye and to an ocularly hypertensive rabbit eye. The intraocular pressure of the two rabbit eyes (normal and ocularly hypertensive) is reduced significantly and measured at intervals of 6 hours.
The S isomer of betaxolol and its pharmaceutically-acceptable salts can be used for the treatment of cardiovascular diseases and, in particular, for coronary complaints, complaints affecting the myocardium and disorders of the heart rate, and for the treatment of glaucoma.
The invention consequently includes pharmaceutical compositions containing (S)(-)-betaxolol, or a pharmaceutically-acceptable acid addition salt thereof, in combination with any excipient suitable for oral, rectal or parenteral administration.
Examples of suitable pharmaceutical forms are tablets, coated tablets, gelatine capsules, ordinary capsules, cachets, solutions and suspensions to be taken orally, suppositories and stabilised and/or buffered injectable solutions, prepared in advance or for immediate use.
The daily dosage can range from 5 to 50 mg of (S)(-) betaxolol.
For the treatment of glaucoma, the concentration of the eye solutions can range from 0.25 to 3% of (S)(-) betaxolol.

Claims (8)

1. (S)(-) Betaxolol oftheformula:
and its pharmaceutically-acceptable acid addition salts.
2. (S)(-) Betaxolol maleate.
3. A process for the preparation of (S)(-) betaxolol which comprises reacting 4-(2-cyclopropylmethoxyethyl)phenol with the (S) oxazolidine of the formula:
in an organic solvent in the presence , a base.
4. A process according to claim 3 in which the organic solvent is dimethylformamide and the base is sodium hydride.
5. A process according to claim 3 or 4 followed by the step of converting (S)(-) betaxolol so obtained by a method known perse into a pharmaceutically-acceptable acid addition salt.
6. A process for the preparation of (S)( - ) betaxolol, and pharmaceutically-acceptable acid addition salts thereof, substantially as hereinbefore described with especial reference to the foregoing Example.
7. Pharmaceutical compositions which comprise, as active ingredient, (S)(-) betaxolol, or a pharmaceutically-acceptable acid addition salt thereof, in association with a pharmacologically-acceptable excipient.
8. (S)(-) Betaxolol and pharmaceutically-acceptable acid addition salts thereof for use as medicaments and, more especially, for the treatment of cardiovascular diseases and, in particular, for coronary complaints, complaints affecting the myocardium and disorders of the heart rate, and for the treatment of glaucoma.
GB08331038A 1982-11-22 1983-11-21 S isomer of betaxolol its preparation and its application in therapy Expired GB2130585B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR8219506A FR2536390B1 (en) 1982-11-22 1982-11-22 ISOMERS OF BETAXOLOL, ITS PREPARATION AND ITS APPLICATION IN THERAPEUTICS

Publications (3)

Publication Number Publication Date
GB8331038D0 GB8331038D0 (en) 1983-12-29
GB2130585A true GB2130585A (en) 1984-06-06
GB2130585B GB2130585B (en) 1985-12-04

Family

ID=9279382

Family Applications (1)

Application Number Title Priority Date Filing Date
GB08331038A Expired GB2130585B (en) 1982-11-22 1983-11-21 S isomer of betaxolol its preparation and its application in therapy

Country Status (13)

Country Link
JP (1) JPS59108745A (en)
AU (1) AU559204B2 (en)
BE (1) BE898277A (en)
CH (1) CH658049A5 (en)
DE (1) DE3341983A1 (en)
FR (1) FR2536390B1 (en)
GB (1) GB2130585B (en)
IE (1) IE56282B1 (en)
IL (1) IL70282A0 (en)
IT (1) IT1169131B (en)
LU (1) LU85099A1 (en)
NL (1) NL8304000A (en)
ZA (1) ZA838682B (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4760182A (en) * 1985-02-07 1988-07-26 Torcan Chemical Ltd. Process for preparing substituted phenol ethers via oxazolidine-structure intermediates
US6258350B1 (en) 1999-01-20 2001-07-10 Alcon Manufacturing, Ltd. Sustained release ophthalmic formulation
US7001615B1 (en) 2001-12-07 2006-02-21 Alcon, Inc. Sustained release ophthalmic, otic and nasal suspension
US20100113606A1 (en) * 2008-11-05 2010-05-06 Auspex Pharmaceuticals, Inc. Aminopropanol modulators of beta-1 adrenergic receptor

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2330383A1 (en) * 1975-11-06 1977-06-03 Synthelabo NEW PHENOL SUBSTITUTE ETHERS, THEIR SALTS, THEIR PREPARATION AND THE MEDICINAL PRODUCTS CONTAINING THEM
US4294966A (en) * 1978-07-28 1981-10-13 Ciba-Geigy Corporation Process for inverting the configuration in optically active compounds
US4342783A (en) * 1980-06-30 1982-08-03 Synthelabo Anti-glaucoma agent

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4760182A (en) * 1985-02-07 1988-07-26 Torcan Chemical Ltd. Process for preparing substituted phenol ethers via oxazolidine-structure intermediates
US6258350B1 (en) 1999-01-20 2001-07-10 Alcon Manufacturing, Ltd. Sustained release ophthalmic formulation
US7001615B1 (en) 2001-12-07 2006-02-21 Alcon, Inc. Sustained release ophthalmic, otic and nasal suspension
US20100113606A1 (en) * 2008-11-05 2010-05-06 Auspex Pharmaceuticals, Inc. Aminopropanol modulators of beta-1 adrenergic receptor

Also Published As

Publication number Publication date
IE56282B1 (en) 1991-06-05
IT1169131B (en) 1987-05-27
AU559204B2 (en) 1987-02-26
IL70282A0 (en) 1984-02-29
JPS59108745A (en) 1984-06-23
IT8323803A0 (en) 1983-11-21
GB8331038D0 (en) 1983-12-29
FR2536390A1 (en) 1984-05-25
BE898277A (en) 1984-05-21
LU85099A1 (en) 1985-07-17
FR2536390B1 (en) 1986-03-21
AU2155883A (en) 1984-05-31
ZA838682B (en) 1985-03-27
NL8304000A (en) 1984-06-18
GB2130585B (en) 1985-12-04
DE3341983A1 (en) 1984-05-24
IE832716L (en) 1984-05-22
CH658049A5 (en) 1986-10-15

Similar Documents

Publication Publication Date Title
RU2089550C1 (en) 1,4-benzothiazepine derivative
JPH03153626A (en) Reduction or maintenance of intraocular pressure using (2-imidazoline-2-ilamino) quinoxaline
GB1572688A (en) Spirohydantoins
MX2013008131A (en) Lipid-lowering antidiabetic agent.
JPH059430B2 (en)
JP4281993B2 (en) Substituted heterocyclic-norbornylamino derivatives, their preparation, their use as pharmaceuticals or diagnostics, and pharmaceuticals containing them
JPS6144868B2 (en)
CA2392038A1 (en) Crystalline form of (s)-2 ethoxy-3-[4-(2-{4-methanesulfonyloxyphenyl} ethoxy) phenyl] propanoic acid
US3542870A (en) 1 - (3,5 - dihalo - 4 - hydroxy - phenyl) - 2 - (2-aryloxy or 2 - arylalkyl - isopropylamino)-propanols
KR840001836B1 (en) Process for the preparation of 9-aminoalkyl fluorenes
GB2130585A (en) S isomer of betaxolol, its preparation and its application in therapy
US4134991A (en) Derivatives of 2-(3-phenyl-2-aminopropionyloxy)-acetic acid
EP0556872A1 (en) Use of 2,2-dimethyl chromene derivatives for the treatment of asthma
US6538012B2 (en) Amlodipine hemimaleate
KR920005827B1 (en) Benzothiadiazepine derivatives
DE60010711T2 (en) AMIDO SPIROPIPERIDINE PROMOTES THE RELEASE OF GROWTH HORMONES
US4847403A (en) 2-Isopropyl-2-(2-methylphenyl)-5-(N-methyl-N-homoveratrylamino)-valeronitrile and method for producing same
AU619049B2 (en) New 1,4-dihydropyridinederivative, namely (-)-2-{(2- aminoethoxy) ethoxy)-4-(2,3-dichlorophenyl)-3- ethoxycarbonyl-50methoxycarbonyl-6-methyl}-1,4- dihydropyridine, process for preparing it and pharmaceutical compositions containing it
EP0050072A1 (en) Cyclopropyl methyl piperazines, process for their preparation and their use in therapeutics
US4820837A (en) 1-hydroxy-oxo-5H-pyrido(3,2-a)phenoxazine-3-carboxylic acid esters
JP3562770B2 (en) Benzazepin-2-one derivatives
US20050014747A1 (en) Dihydrothiazine prodrugs of thiazolium agents
JP2003026677A (en) 3-phenyl-3,7-diazabicyclo[3,3,1]nonane compound, pharmaceutical comprising the same, use thereof and process for preparing the same
SU1326572A1 (en) Hydrochloride of 1,3-bis-(dimethylamino)-2-propyl-4-chlorphenoxyacetate possessing stimulating brain effect
NZ199008A (en) 2,3,3a,4,5,6-hexahydro-ih-indolo(3,2,1-de)(1,5)-naphthyridines

Legal Events

Date Code Title Description
732E Amendments to the register in respect of changes of name or changes affecting rights (sect. 32/1977)